Cargando…
A pharmacovigilance study of association between proton pump inhibitor and dementia event based on FDA adverse event reporting system data
Proton pump inhibitor (PPI) was widely used around the world. Studies suggested conflicting results between PPI treatment and dementia event. This study examined the association between six PPI agents and dementia event by mining the US FDA Adverse Event Reporting System (FAERS) database from 2004 t...
Autores principales: | Wu, Bin, Hu, Qiaozhi, Tian, Fangyuan, Wu, Fengbo, Li, Yuwen, Xu, Ting |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139970/ https://www.ncbi.nlm.nih.gov/pubmed/34021217 http://dx.doi.org/10.1038/s41598-021-90108-7 |
Ejemplares similares
-
Proton pump inhibitors associated acute kidney injury and chronic kidney disease: data mining of US FDA adverse event reporting system
por: Wu, Bin, et al.
Publicado: (2021) -
An observational, retrospective, comprehensive pharmacovigilance analysis of hydroxychloroquine-associated cardiovascular adverse events in patients with and without COVID-19
por: Luo, Min, et al.
Publicado: (2022) -
Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2022) -
Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023) -
Proton Pump Inhibitors and the Risk for Fracture at Specific Sites: Data Mining of the FDA Adverse Event Reporting System
por: Wang, Liwei, et al.
Publicado: (2017)